DNA · All filings · Read this filing
What changed 10-Q
Item 5. Other Information
2024-08-08 compared with 2024-05-09 · 3 added, 2 removed, 31 unchanged (14% of the section changed)
7 unchanged sentences
(incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed with the SEC on October 27, 2023).
−Removed: 10.1* Form of Stock Option Agreement for 2024 Founder Award Program, granted under the Ginkgo Bioworks Holdings, Inc.
−Removed: 2021 Incentive Award Plan .
31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
Ginkgo Bioworks Holdings, Inc.
+Added: August 8, 2024
/s/ Jason Kelly
Chief Executive Officer (Principal Executive Officer)
+Added: August 8, 2024
/s/ Mark Dmytruk
Chief Financial Officer (Principal Financial Officer)
+Added: August 8, 2024
/s/ Steven Coen
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.